Get the Stockscreener App
0.5506
0.08%
0.00045
X 4 Pharmaceuticals Inc stock is traded at $0.5506, with a volume of 707.55K.
It is up +0.08% in the last 24 hours and down -21.57% over the past month.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$0.5501
Open:
$0.5557
24h Volume:
707.55K
Relative Volume:
0.14
Market Cap:
$93.82M
Revenue:
-
Net Income/Loss:
$-16.76M
P/E Ratio:
-6.8819
EPS:
-0.08
Net Cash Flow:
$-132.97M
1W Performance:
-21.36%
1M Performance:
-21.57%
6M Performance:
-12.76%
1Y Performance:
-35.39%
1-Day Range:
$0.5335
$0.57
1-Week Range:
$0.50
$0.67
52-Week Range:
$0.2612
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
0.5506 | 93.82M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.87 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.80 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.64 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Fierce Biotech Layoff Tracker 2025: Viracta shuts down; Layoffs hit Frontier - Fierce Biotech
X4 Pharmaceuticals Inc [XFOR] Records 200-Day SMA of $0.7110 - Knox Daily
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - Marketscreener.com
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services - PR Newswire
X4 Pharma's Major Restructuring: 43 Jobs Cut as Company Pivots to Core Drug Development - StockTitan
Gaining Ground: X4 Pharmaceuticals Inc (XFOR) Closes Lower at 0.60, Down -0.73 - The Dwinnex
What is X4 Pharmaceuticals Inc (XFOR) Stock Return on Shareholders’ Capital? - SETE News
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Keeping an Eye on X4 Pharmaceuticals Inc (XFOR) After Insider Trading Activity - Knox Daily
X4 Pharma's Latest Employee Stock Plan: Strategic Move to Attract Top Talent - StockTitan
A closer look at X4 Pharmaceuticals Inc’s (XFOR) current quarter earnings projections - US Post News
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Position Lifted by JPMorgan Chase & Co. - Defense World
Top 10 pharma companies in India by market cap [2025] - Forbes India
Vanguard Group Inc Reduces Stake in X4 Pharmaceuticals Inc - GuruFocus.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development - GlobeNewswire
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition - Star Local Media
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa Sells 74,773 Shares - MarketBeat
Mark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock - MarketBeat
Insider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells 76,473 Shares of Stock - MarketBeat
X4 Pharmaceuticals CFO Mostafa Adam S. sells $33,946 in stock - MSN
X4 Pharmaceuticals CFO Mostafa Adam S. sells $33,946 in stock By Investing.com - Investing.com South Africa
x4 pharmaceuticals CEO sells shares worth $34,718 By Investing.com - Investing.com Nigeria
x4 pharmaceuticals CEO sells shares worth $34,718 - Investing.com India
X4 Pharmaceuticals' chief medical officer sells $5,284 in stock - Investing.com India
x4 Pharmaceuticals CCO Mark Baldry sells $13,241 in stock - Investing.com
x4 Pharmaceuticals chief commercial officer sells $13,241 in stock By Investing.com - Investing.com Australia
x4 Pharmaceuticals chief commercial officer sells $13,241 in stock - Investing.com
x4 Pharmaceuticals CCO Mark Baldry sells $13,241 in stock By Investing.com - Investing.com UK
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
META_TITLE_QUOTE - Yahoo Finance
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixaforlicenced to Norgine for commercialisation in Europe. - Yahoo Finance
X4 Pharma stock gains as lead drug under EU review (XFOR) - Seeking Alpha
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome - Yahoo Finance
Barclays PLC Buys 183,861 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Quantisnow
January 2025's Top US Penny Stocks To Consider - Simply Wall St
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price - Simply Wall St
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
EVP Research Swayze Eric converted options into 19,160 shares and sold $235,678 worth of shares (7,176 units at $32.84), increasing direct ownership by 35% to 45,670 units (SEC Form 4) - Quantisnow
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
X4 Pharmaceuticals (NASDAQ:XFOR) Earns Buy Rating from HC Wainwright - Defense World
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):